Ethic Inc. Buys 16,040 Shares of Novo Nordisk A/S $NVO

Ethic Inc. increased its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 10.0% in the third quarter, Holdings Channel reports. The firm owned 175,739 shares of the company’s stock after buying an additional 16,040 shares during the quarter. Ethic Inc.’s holdings in Novo Nordisk A/S were worth $6,662,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. StoneX Group Inc. bought a new position in Novo Nordisk A/S during the 3rd quarter worth approximately $436,000. Kornitzer Capital Management Inc. KS increased its stake in Novo Nordisk A/S by 8.4% in the third quarter. Kornitzer Capital Management Inc. KS now owns 25,324 shares of the company’s stock valued at $960,000 after purchasing an additional 1,965 shares in the last quarter. Verus Capital Partners LLC increased its stake in Novo Nordisk A/S by 61.5% in the third quarter. Verus Capital Partners LLC now owns 12,640 shares of the company’s stock valued at $479,000 after purchasing an additional 4,811 shares in the last quarter. Abacus Wealth Partners LLC increased its stake in Novo Nordisk A/S by 4.1% in the third quarter. Abacus Wealth Partners LLC now owns 16,468 shares of the company’s stock valued at $624,000 after purchasing an additional 650 shares in the last quarter. Finally, United Advisor Group LLC raised its holdings in Novo Nordisk A/S by 10.9% in the third quarter. United Advisor Group LLC now owns 8,741 shares of the company’s stock worth $331,000 after purchasing an additional 856 shares during the period. Institutional investors own 11.54% of the company’s stock.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo’s third-quarter results and raised guidance have helped support investor interest. The Wegovy pill is reportedly seeing strong sales, with more than 5 million prescriptions, suggesting it may expand the market rather than simply replace injections. Novo Up 4% in a Month: How Should Investors Approach the Stock Now? Wegovy pill prescriptions
• Positive Sentiment: Reports of liver improvements in some Wegovy patients point to potential additional clinical benefits and patient demand beyond weight loss. Novo Nordisk reports liver improvements with Wegovy in some patients
• Neutral Sentiment: Novo’s ongoing share-repurchase program, part of a plan of up to DKK 15 billion over 12 months, may provide some support for shareholders but is not a new growth catalyst. Novo Nordisk share repurchase programme
• Neutral Sentiment: Some crypto-market commentary says Binance futures accounts are leaning long on NVO, a speculative positioning signal rather than evidence of a change in the company’s fundamentals. Binance Futures Accounts Lean Long on Novo Nordisk
• Negative Sentiment: The FDA is requiring GLP-1 drugs, including Novo’s treatments, to carry warnings about a rare eye condition that can cause permanent vision loss. The label change may increase safety concerns among patients and prescribers. US FDA orders new eye risk warnings for Ozempic, Zepbound
• Negative Sentiment: Competition from Eli Lilly and pricing pressure continue to cloud Novo’s longer-term growth outlook. Commentary also highlights weaker earnings and a loss of market leadership in injectable GLP-1 drugs, tempering enthusiasm about pill growth. Competition and pricing pressures Novo Nordisk’s 2026 transition year

Novo Nordisk A/S Price Performance

NYSE NVO opened at $41.40 on Tuesday. The business has a 50 day simple moving average of $40.50 and a 200 day simple moving average of $43.77. Novo Nordisk A/S has a 52-week low of $35.12 and a 52-week high of $64.16. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.66 and a current ratio of 0.87. The stock has a market cap of $184.85 billion, a price-to-earnings ratio of 10.84, a PEG ratio of 1.42 and a beta of 0.70.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on NVO shares. Citigroup reissued a “neutral” rating on shares of Novo Nordisk A/S in a research report on Friday, October 9th. UBS Group reissued a “neutral” rating on shares of Novo Nordisk A/S in a report on Monday, September 21st. Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of Novo Nordisk A/S in a research report on Tuesday, September 29th. Weiss Ratings downgraded Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, October 8th. Finally, DZ Bank reiterated a “neutral” rating on shares of Novo Nordisk A/S in a report on Thursday, August 6th. Five equities research analysts have rated the stock with a Buy rating, sixteen have assigned a Hold rating and five have assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $59.44.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish pharmaceutical company focused on treatments for diabetes, obesity and other serious chronic diseases. Its portfolio includes insulin and other diabetes medicines, as well as obesity treatments such as Wegovy and diabetes treatments such as Ozempic and Rybelsus.

The company also develops medicines for rare blood and endocrine disorders, including hemophilia and growth disorders. Its products are sold in markets around the world.

Novo Nordisk traces its roots to Danish insulin companies founded in the 1920s; the two organizations that became Novo Nordisk merged in 1989.